Video

Episode 13 - Treatment Challenges for Progressive Disease

Because there aren’t treatment options available for the management of progressive multiple sclerosis (MS), Patricia K. Coyle, MD, explains the challenges clinicians are faced with when treating patients who transition into a progressive stage of the disease.

Dr Coyle and Leslie Fish, PharmD, explain that although the topic of when to end therapy for patients who transition into a worsening stage is controversial, it is necessary to make personalized treatment decisions.

Dr Fish further explains how the rising costs of agents for the treatment MS further complicate management of MS and affect a clinician’s decision about when to begin or end therapy for a patient.


Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP)
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo